Date of Award
Master of Science
Dr. Shengwu Ma
Human serum transferrin (hsTf) is well characterized for its ability to transport fused therapeutics throughout the body upon oral administration. Glucagon-like peptide-1 (GLP-1) is one such therapeutic, effective against Type II diabetes that could benefit from such a fusion strategy. However, therapeutic use of hsTf and GLP-1 is limited by their generation using current recombinant protein production platforms. This project assesses the viability of accumulating hsTf and GLP-1 independently in transgenic plants as a novel source for the generation o f both recombinant proteins. Here, nuclear-transformed tobacco plants stably accumulating either hsTf or a synthetic GLP-1 decamer have been developed. Plant-derived hsTf was shown to reversibly bind iron in vitro and the biological activity of GLP-1 was confirmed by its ability to stimulate insulin secretion from a pancreatic cell-line in vitro. Overall, results warrant future hsTf-GLP-1 genetic fusions in transgenic plants intended for enhanced bioavailability of GLP-1 upon oral administration
Brandsma, Martin E., "FRAMEWORK ESTABLISHMENT OF TRANSGENIC PLANTAE FACILITATING SYSTEMIC DELIVERY OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)" (2009). Digitized Theses. 4055.